Company intelligence / Profile preview

Mirapharm

Miami, Florida, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

MIRA Pharmaceuticals is developing oral small molecule drugs for neuroscience indications. Its two main candidates, Ketamir-2 (an oral ketamine analog) and MIRA-55 (a pharmaceutical marijuana analog), are in preclinical and early clinical investigation and have not yet reported clinical efficacy results. Both are under investigation for CNS disorders including neuropathic pain, depression, PTSD, anxiety, and early cognitive decline. Neither is a controlled substance in the US per DEA review.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small moleculeSynthetic cannabinoid analogue
Industry: Biotech

Beyond the preview

Go deeper on Mirapharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirapharm.

Explore the full profile